U.S., Oct. 1 -- ClinicalTrials.gov registry received information related to the study (NCT07198620) titled 'A Real-World Study of IBI351 for KRAS G12C+ NSCLC in China' on Sept. 22.
Brief Summary: This study is a retrospective, multicenter, real-world investigation designed to evaluate the efficacy and safety of IBI-351 in Chinese patients with advanced non-small cell lung cancer (NSCLC) harboring a KRAS G12C mutation in a real-world setting. A total of 600 patients with KRAS G12C-mutated advanced NSCLC who received treatment with IBI-351 between August 2024 and August 2025 will be retrospectively enrolled. Descriptive statistical methods will be used to summarize the baseline characteristics, demographic data, and medication profiles of th...